MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyae364

Медицинская библиотека · The oncologist · 2025

A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.

Perez Kimberly, Kulke Matthew H, Zheng Hui, Allen Jill, Clark Jeffrey, Enzinger Andrea C, Enzinger Peter C, Johnson Bruce E, McCleary Nadine J, Parikh Aparna, Patel Anuj, Rubinson Douglas, Yurgelun Matthew B, Ramsey Kaitlyn, Johnson Emma, Graham Christopher, Chan Jennifer A

СтатьяКлиническое исследование II фазыПеревод в очереди

Аннотация

OBJECTIVES

Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.

METHODS

We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET. Patients were treated with ramucirumab 8 mg/kg intravenously on days 1 and 15 of each 28-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints toxicity, radiographic and biochemical tumor response rate, and overall survival (OS).

RESULTS

The trial enrolled 43 patients. Primary tumor sites included small intestine 20 (46%), lung 10 (23%), thymus 3 (7%), rectum 1(2%), kidney 1(2%), and unknown primary 8(18%). Median PFS was 14.2 months (95% CI, 9.0-25.6 months), and median OS was 24.9 months (95% CI, 20.7-43.1 months). Best response by RECIST 1.1: partial response 5% (95% CI, 0.6%-15.8%). Chromogranin A levels dropped by at least 50% in 10% of the 37 patients who had elevated levels at baseline. Most common all-grade adverse events included fatigue (84%) and hypertension (84%).

CONCLUSION

Ramucirumab demonstrated efficacy and safety in this single-arm phase II trial. These findings support the continued evaluation of angiogenesis inhibitors in the treatment of NET.

CLINICAL TRIAL REGISTRATION: NCT02795858.

Для цитирования: Perez Kimberly, Kulke Matthew H, Zheng Hui, Allen Jill, Clark Jeffrey, Enzinger Andrea C, Enzinger Peter C, Johnson Bruce E, McCleary Nadine J, Parikh Aparna, Patel Anuj, Rubinson Douglas, Yurgelun Matthew B, Ramsey Kaitlyn, Johnson Emma, Graham Christopher, Chan Jennifer A. A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.. The oncologist. 2025. DOI: 10.1093/oncolo/oyae364.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.